인쇄하기
취소

Japanese health authorities approves concurrent therapy of Fastic

Published: 2009-01-19 06:58:00
Updated: 2009-01-19 06:58:00
Tokyo-headquartered pharmaceutical company, Astellas announced that an additional indication for nateglinide, has been recently approved in Japan, according to Ildong Pharm.

Nateglinide is a fast-acting postprandial hypoglycemic agent for use in combination therapy. It was developed by the Astellas along with another Japanese pharma company, Ajinomoto.

Ildong plans to file a local applica...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.